6 research outputs found
Absorbent microbiopsy sampling and RNA extraction for minimally invasive, simultaneous blood and skin analysis
Conventional skin biopsy limits the clinical research that involves cosmetically sensitive areas or pediatric applications due to its invasiveness. Here, we describe the protocol for using an absorbent microneedle-based device, absorbent microbiopsy, for minimally invasive sampling of skin and blood mixture. Our goal is to help facilitate rapid progress in clinical research, the establishment of biomarkers for skin disease and reducing the risk for clinical research participants. In contrast to conventional skin biopsy techniques, the absorbent microbiopsy can be performed within seconds and does not require intensive training due to its simple design. In this report, we describe the use of absorbent microbiopsy, including loading and application, on a volunteer. Then, we show how to isolate RNA from the absorbed sample. Finally, we demonstrate the use of quantitative reverse transcription PCR (RT-qPCR) to quantify mRNA expression levels of both blood (CD3E and CD19) and skin (KRT14 and TYR). The methods that we describe utilize off the shelf kits and reagents. This protocol offers a minimally invasive approach for simultaneous sampling of skin and blood within the same absorbent microbiopsy matrix. We have found human ethics committees, clinicians and volunteers to be supportive of this approach to dermatological research.Benson U.W. Lei, Miko Yamada, Van L.T. Hoang, Paul J. Belt, Mark H. Moore, Lynlee L. Lin, Ross Flewell-Smith, Nhung Dang, Shoko Tomihara, Tarl W. Pro
Microbiopsy-based minimally invasive skin sampling for molecular analysis is acceptable to Epidermolysis Bullosa Simplex patients where conventional diagnostic biopsy was refused
Letter to the EditorAbstract not available.Miko Yamada, Elizabeth Melville, Allison J. Cowin, Tarl W. Prow, Zlatko Kopeck
A randomized, phase IIa exploratory trial to assess the safety and preliminary efficacy of LEO 43204 in patients with actinic keratosis
Background LEO 43204 is a novel ingenol derivative in development for the treatment of actinic keratosis. Objectives To compare the safety and preliminary efficacy of three doses of LEO 43204 with ingenol mebutate in actinic keratoses (AKs). Methods Patients with at least three visible, discrete, nonkeratotic AKs on four separate selected treatment areas on the forearms received LEO 43204 gel (0路025%, 0路05% and 0路075%) and ingenol mebutate 0路05% gel, by investigator-blinded, randomized allocation, for 2 consecutive days. Patients were assessed at 8 weeks. Primary outcomes included maximum composite local skin response (LSR) score and adverse events (AEs). Secondary outcomes included a reduction in the number of visible AKs. Results Forty patients completed the trial. For all treatments, mean LSR scores peaked at week 1, and were below baseline by week 8. Mean maximum composite LSR scores for LEO 43204 0路025%, 0路05% and 0路075% were 9路2 (Dunnett adjusted P = 0路02), 10路1 (Dunnett adjusted P = 0路90) and 11路2 (Dunnett adjusted P < 0路01), respectively, vs. ingenol mebutate 0路05% gel (10路0). The most frequent AEs across all treatments were application site pruritus, burning sensation and tenderness. Mean reduction in the number of AKs was comparable for ingenol mebutate and the two lowest doses of LEO 43204 (71路9-73路1%), but LEO 43204 0路075% gave a significantly larger reduction (81路8%; Dunnett adjusted P = 0路04). Conclusions LEO 43204 had a similar safety profile to ingenol mebutate and a dose-response relationship for LSRs was demonstrated. The highest LEO 43204 dose (0路075%) significantly reduced the AK count when compared with ingenol mebutate